期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 117, 期 5, 页码 1204-1212出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI31446
关键词
-
资金
- NCI NIH HHS [R01 CA105216-02, 5P50 CA 083638, R01 CA105216, 1R01 CA 104679, P50 CA083638, 5R01 CA 105216] Funding Source: Medline
The transfusion of T cells, also called adoptive T cell therapy, is an effective treatment for viral infections and has induced regression of cancer in early-stage clinical trials. However, recent advances in cellular immunology and tumor biology are guiding new approaches to adoptive T cell therapy. For example, use of engineered T cells is being tested as a strategy to improve the functions of effector and memory T cells, and manipulation of the host to overcome immunotoxic effects in the tumor microenvironment has led to promising results in early-stage clinical trials. Challenges that face the field and must be addressed before adoptive T cell therapy can be translated into routine clinical practice are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据